{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:32:01Z","timestamp":1761093121316,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.urolonc.2020.10.009","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T09:06:55Z","timestamp":1605604015000},"page":"137-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer"],"prefix":"10.1016","volume":"39","author":[{"given":"Alvaro","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Robert","family":"Siemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Koti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.10.009_bib0001","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus calmette-guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0002","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0003","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \"a phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2020.10.009_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000474915","article-title":"Optimal BCG treatment of superficial bladder cancer as defined by American trials","volume":"21","author":"Lamm","year":"1992","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0005","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0006","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0007","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0008","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0009","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0010","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin connaught strain for bladder cancer patients","author":"Ourfali","year":"2019","journal-title":"Eur Urol Focus"},{"journal-title":"Eur Urol","year":"2020","author":"Grimm","key":"10.1016\/j.urolonc.2020.10.009_bib0011"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0012","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00262-011-1121-4","article-title":"Mycobacteria activate \u03b3\u03b4 T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy","volume":"61","author":"Fowler","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/14712598.2016.1134483","article-title":"Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin","volume":"16","author":"Morales","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0014","first-page":"24","article-title":"Mycobacterial strains that stimulate the immune system most efficiently as candidates for the treatment of bladder cancer","volume":"20","author":"Yuksel","year":"2011","journal-title":"J Mol Microbiol Biotechnol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0015","unstructured":"Koti M, Chenard S, Nersesian S, Vidotto T, Morales A, Siemens DR. Investigating the STING pathway to explain mechanisms of BCG failures in non-muscle invasive bladder cancer: prognostic and therapeutic implications."},{"key":"10.1016\/j.urolonc.2020.10.009_bib0016","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.vaccine.2019.11.060","article-title":"Licensed bacille Calmette-Guerin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation","volume":"38","author":"Angelidou","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.10.009_bib0018","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920304816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:20:23Z","timestamp":1761042023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920304816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1078143920304816"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.10.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}